| [1］ Ferté-Delbende C, Catteau-Jonard S, Barrière P, et al.Evaluation of the ovarian reserve［J］.J Gynecol Obstet Biol Reprod (Paris), 2010,39(8 Suppl 2):S27-33. [2］ La Marca A, Argento C, Sighinolfi G, et al.Possibilities and limits of ovarian reserve testing in ART［J］.Curr Pharm Biotechnol,2012, 13(3):398-408. [3］ Alshiek JA, Lessing JB, Amit A,et al.Anti mullerian hormone (AMH)--is it a new reliable marker of the ovarian reserve:its role in predicting the ovarian response in assisted reproductive technology (ART)［J］.Harefuah,2012,151(7):416-420. [4］ Tan R, Pu D, Liu L, et al.Comparisons of inhibin B versus antimüllerian hormone in poor ovarian responders undergoing in vitro fertilization［J］.Fertil Steril, 2011,96(4):905-911. [5］ Zarchi1 MK, Mousavi A, Gilani MM,et al.Fertility sparing treatments in young patients with gynecological cancers: iranian experience and literature review［J］.Asian Pacific Journal of Cancer Prevention, 2011,12: 1887-1892. [6］ Plante M, Renaud MC, Hoskins IA,et al.Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer:a series of 50 pregnancies and review of the literature［J］.Gynecol Oncol, 2005,98(1):3-10. [7］ Jamal W, Phillips SJ, Hemmings R,et al.Successful pregnancy following novel IVF protocol and transmyometrial embryo transfer after radical vaginal trachelectomy［J］.Reprod Biomed Online, 2009,18(5):700-703. [8］ Siristatidis C, Sergentanis TN, Kanavidis P, et al.Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer--a systematic review and meta-analysis［J］. Hum Reprod Update, 2012,18:294-299. [9］ Silva-Filho A, Carmo G, Athayde G, et al. Safe fertility-preserving management in gynecological malignancies［J］. Arch Gynecol Obstet,2007, 275:321-330. [10］ Wu HM, Lai CH, Huang HY, et al.A successful live twin birth by in vitro fertilization after conservative treatment of recurrent endometrial cancer［J］.Chang Gung Med J, 2008,31(1):102-106. [11］ Bukovic D, Segregur J, Radan M, et al.Extracorporeal fertilization in the world and in Croatia［J］.Med Arh, 2011,65(5):312-316. [12］ Kanat-Pektas M, Ozat M, Gungor T, et al.Fertility outcome after conservative surgery for borderline ovarian tumors: a single center experience［J］.Arch Gynecol Obstet, 2011,284(5):1253-1258. [13］ Anita AN, Rushdan MN.Reproductive function after treatment of ovarian germ cell malignancy［J］.Med J Malaysia, 2012,67(1):71-76. [14］ Cabenda-Narain NE, Jansen FW, Dieben SW, et al.Conservatively treated borderline ovarian tumours, followed by IVF treatment: a case series［J］.J Obstet Gynaecol, 2011,31(4):327-329. [15］ Bocca S, Dedmond D, Jones E, et al.Successful extracorporeal mature oocyte harvesting after laparoscopic oophorectomy following controlled ovarian hyperstimulation for the purpose of fertility preservation in a patient with borderline ovarian tumor［J］.J Assist Reprod Genet, 2011,28(9):771-772. [16］ Záhumensky J, Feldmár P, Kuera E, et al.Reproductive functions in women after cancer therapy［J］. Klin Onkol,2012,25(3):173-177. [17］ Sabatini ME, Wolkovich AM, Macklin EA, et al.Pronuclear embryo cryopreservation experience: outcomes for reducing the risk of ovarian hyperstimulation syndrome and for fertility preservation in cancer patients［J］.J Assist Reprod Genet, 2011,28(3):279-284. [18］ Das M, Shehata F, Moria A, et al.Ovarian reserve, response to gonadotropins, and oocyte maturity in women with malignancy［J］.Fertil Steril, 2011,96(1):122-125. [19］ Das M, Shehata F, Son WY,er al.Ovarian reserve and response to IVF and in vitro maturation treatment following chemotherapy［J］.Hum Reprod, 2012,27(8):2509-2511. |
